{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T10:49:02Z","timestamp":1784371742093,"version":"3.55.0"},"reference-count":12,"publisher":"Informa UK Limited","issue":"9-11","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Gilead Sciences, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Xenobiotica"],"published-print":{"date-parts":[[2022,11,2]]},"DOI":"10.1080\/00498254.2022.2159569","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T10:32:59Z","timestamp":1671705179000},"page":"973-985","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Human and nonclinical disposition of [<sup>14<\/sup>C]bictegravir, a potent integrase strand-transfer inhibitor for the treatment of HIV-1 infection"],"prefix":"10.1080","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3806-5227","authenticated-orcid":false,"given":"Raju","family":"Subramanian","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ling","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Wang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Wang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Hao","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolun","family":"Jin","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9505-333X","authenticated-orcid":false,"given":"Yurong","family":"Lai","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Murray","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Wijaya","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Zhang","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bill J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,1,6]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01834-15"},{"key":"CIT0002","unstructured":"CDER (Center for Drug Evaluation and Research). 2016. Guidance for industry: safety testing of drug metabolites. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration. [accessed 2022 Dec 7]. https:\/\/www.fda.gov\/media\/72279\/download."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"CIT0004","unstructured":"EMA (European Medicines Agency). 2018. Public assessment report Biktarvy\u00ae. [accessed 2022 Dec 7]. https:\/\/www.ema.europa.eu\/documents\/assessment-report\/biktarvy-epar-public-assessment-report_en.pdf. Last."},{"key":"CIT0005","unstructured":"FDA (Food and Drug Administration). 2018. Biktarvy\u00ae (bictegravir, emtricitabine, and tenofovir alafenamide) tablets, for oral use. [accessed 2022 Dec 10]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210251s000lbl.pdf."},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1021\/js970486q"},{"key":"CIT0007","unstructured":"Jin H, Pyun H, Smith BJ, Subramanian R, Wang J, inventors; Gilead Sciences, Inc., assignee. 2019 Jan 18. Metabolites of bictegravir. International Patent WO\/2019\/144015 Al."},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.106027"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz624"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-16"},{"key":"CIT0011","unstructured":"Wang J, Lazerwith S, Morganelli P, Pyun H, Jin H, Tang J, Matles M, Mwangi J, Wang K, Eisenberg G, et\u00a0al. 2017. P16. Prediction of bictegravir human pharmacokinetics from protein binding and in\u00a0vitro-in\u00a0vivo correlation. Poster Session Presented at: 21st North American ISSX Meeting; Sep 24\u2009\u2212\u200928; Providence, RI."},{"issue":"1","key":"CIT0012","first-page":"A74","volume":"93","author":"Zhang H","year":"2017","journal-title":"Sex Transm Infect"}],"container-title":["Xenobiotica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/00498254.2022.2159569","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T12:57:09Z","timestamp":1674565029000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/00498254.2022.2159569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":12,"journal-issue":{"issue":"9-11","published-print":{"date-parts":[[2022,11,2]]}},"alternative-id":["10.1080\/00498254.2022.2159569"],"URL":"https:\/\/doi.org\/10.1080\/00498254.2022.2159569","relation":{},"ISSN":["0049-8254","1366-5928"],"issn-type":[{"value":"0049-8254","type":"print"},{"value":"1366-5928","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ixen20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ixen20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}